<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04850027</url>
  </required_header>
  <id_info>
    <org_study_id>MALAREC</org_study_id>
    <nct_id>NCT04850027</nct_id>
  </id_info>
  <brief_title>MRI-guided Lateral Lymph Node Dissection in Rectal Cancer</brief_title>
  <official_title>MAgnetic Resonance Imaging Guided LAteral Lymph Node Dissection in Lower REctal Cancer - A Multicenter, Prospective, Registry Study (MALAREC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China-Japan Union Hospital, Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Suzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of China Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Cancer Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the oncological outcome of lateral lymph node dissection in low rectal cancer&#xD;
      based on MRI&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our study design is a multicenter, prospective, registry study.&#xD;
&#xD;
      We would enroll 268 patients with lower rectal cancer whose preoperative MRI showed laterally&#xD;
      lymph node diameter ≥ 5mm.&#xD;
&#xD;
      The postoperative adjuvant chemoradiotherapy is determined by the pathological results. For&#xD;
      patients of stage II and patients of stage III with unfavorable histologic features, six&#xD;
      months of adjuvant chemotherapy of fluorouracil-based regimen with radiotherapy of 45.0 ~&#xD;
      50.5 Gy are recommended.&#xD;
&#xD;
      The postoperative examination should be performed every three months in the first two years&#xD;
      and every six months in the following three years.&#xD;
&#xD;
      Our study is expected to last five years, of which two years for recruiting patients, three&#xD;
      years for follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Pathological positive rate</measure>
    <time_frame>3-year.</time_frame>
    <description>The proportion of patients with positive lateral lymph node which was confirmed pathologically.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local recurrence rate</measure>
    <time_frame>3-year</time_frame>
    <description>The proportion of patients with local recurrence after 3 years of surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>3-year</time_frame>
    <description>The proportion of patients survived after 3 years of surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>3-year</time_frame>
    <description>The proportion of patients with no disease recurrence and metastasis after 3 years of surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early morbidity rate</measure>
    <time_frame>30 days</time_frame>
    <description>The early morbidity rate is defined as the event observed during operation and within 30 days after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the surgery</measure>
    <time_frame>1 day</time_frame>
    <description>The duration of time between the start and the end of the surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>30 days</time_frame>
    <description>Complications occurring within 30 days after surgery, mainly urinary and sexual functions.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">268</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Lower rectal cancer patients with a LLN ≥ 5mm</arm_group_label>
    <description>Patients with lateral lymph node short diameter ≥ 5mm evaluated by MRI were included.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TME+Lateral lymph node dissection.</intervention_name>
    <description>TME and lateral lymph node dissection is performed in rectal cancer patients with lateral lymph node short diameter ≥ 5 mm.</description>
    <arm_group_label>Lower rectal cancer patients with a LLN ≥ 5mm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Lower rectal cancer patients with lateral lymph node short diameter ≥ 5 mm were included in&#xD;
        the study. TME with lateral lymph node dissection was performed in these patients. LLN&#xD;
        positive rate, local recurrence rate, 3-year overall survival rate, perioperative&#xD;
        complication rate and quality of life were documented and analysed.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18-75 years old&#xD;
&#xD;
          2. Pathologically confirmed as rectal adenocarcinoma&#xD;
&#xD;
          3. The tumor is located in the middle or lower rectum&#xD;
&#xD;
          4. Preoperative MRI assessment is T2-4 N+M0&#xD;
&#xD;
          5. Lateral lymph node short diameter ≥ 5 mm (MRI)&#xD;
&#xD;
          6. Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous history of malignant colorectal tumors&#xD;
&#xD;
          2. Multiple abdominal or pelvic surgeries were performed&#xD;
&#xD;
          3. Complicated with bowel obstruction, perforation or bleeding&#xD;
&#xD;
          4. Patients undergoing palliative surgery&#xD;
&#xD;
          5. Patients with severe liver and kidney dysfunction, cardiopulmonary dysfunction, blood&#xD;
             coagulation dysfunction, or combined with serious underlying diseases that cannot&#xD;
             tolerate surgery&#xD;
&#xD;
          6. Have a history of severe mental illness&#xD;
&#xD;
          7. Pregnant or breastfeeding women （8) Patients previously treated with iliac artery&#xD;
             surgery (or its branches)&#xD;
&#xD;
        (9) R0 resection cannot complete (10) ASA grade ≥ IV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qian Liu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qian Liu, M.D</last_name>
    <phone>01087787110</phone>
    <email>fcwpumch@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qian Liu, M.D</last_name>
      <phone>01087787110</phone>
      <email>fcwpumch@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Zheng Liu, M.D</last_name>
      <phone>01087787111</phone>
      <email>190977026@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Qian Liu, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Baik SH, Kim NK, Lee YC, Kim H, Lee KY, Sohn SK, Cho CH. Prognostic significance of circumferential resection margin following total mesorectal excision and adjuvant chemoradiotherapy in patients with rectal cancer. Ann Surg Oncol. 2007 Feb;14(2):462-9. Epub 2006 Nov 10.</citation>
    <PMID>17096053</PMID>
  </reference>
  <reference>
    <citation>Akiyoshi T, Ueno M, Matsueda K, Konishi T, Fujimoto Y, Nagayama S, Fukunaga Y, Unno T, Kano A, Kuroyanagi H, Oya M, Yamaguchi T, Watanabe T, Muto T. Selective lateral pelvic lymph node dissection in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy based on pretreatment imaging. Ann Surg Oncol. 2014 Jan;21(1):189-96. doi: 10.1245/s10434-013-3216-y. Epub 2013 Aug 21.</citation>
    <PMID>23963871</PMID>
  </reference>
  <reference>
    <citation>Fujita S, Mizusawa J, Kanemitsu Y, Ito M, Kinugasa Y, Komori K, Ohue M, Ota M, Akazai Y, Shiozawa M, Yamaguchi T, Bandou H, Katsumata K, Murata K, Akagi Y, Takiguchi N, Saida Y, Nakamura K, Fukuda H, Akasu T, Moriya Y; Colorectal Cancer Study Group of Japan Clinical Oncology Group. Mesorectal Excision With or Without Lateral Lymph Node Dissection for Clinical Stage II/III Lower Rectal Cancer (JCOG0212): A Multicenter, Randomized Controlled, Noninferiority Trial. Ann Surg. 2017 Aug;266(2):201-207. doi: 10.1097/SLA.0000000000002212.</citation>
    <PMID>28288057</PMID>
  </reference>
  <reference>
    <citation>Ishihara S, Kawai K, Tanaka T, Kiyomatsu T, Hata K, Nozawa H, Morikawa T, Watanabe T. Oncological Outcomes of Lateral Pelvic Lymph Node Metastasis in Rectal Cancer Treated With Preoperative Chemoradiotherapy. Dis Colon Rectum. 2017 May;60(5):469-476. doi: 10.1097/DCR.0000000000000752.</citation>
    <PMID>28383446</PMID>
  </reference>
  <reference>
    <citation>Furuhata T, Okita K, Nishidate T, Ito T, Yamaguchi H, Ueki T, Akizuki E, Meguro M, Ogawa T, Kukita K, Kimura Y, Mizuguchi T, Hirata K. Clinical feasibility of laparoscopic lateral pelvic lymph node dissection following total mesorectal excision for advanced rectal cancer. Surg Today. 2015 Mar;45(3):310-4. doi: 10.1007/s00595-014-0906-4. Epub 2014 May 3.</citation>
    <PMID>24792010</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2021</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lateral lymph node</keyword>
  <keyword>Surgery</keyword>
  <keyword>Magnetic resonance imaging</keyword>
  <keyword>oncological outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data are available from Qian Liu upon request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>The data were available to all the researchers permanently after this study was done.</ipd_time_frame>
    <ipd_access_criteria>All the data will be available to all the relevant researchers in the world upon request. Email: liuqianncc@126.com</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

